- April 22, 2018
- Posted by: Pharmascroll
Expected to hit the market by 2018, Advair generic copy from Novartis now has a revised timeline of 2019. Earlier in February, FDA turned back the probable generic from Novartis directing company to complete a a small bio-equivalence bridging study.
Novartis CEO, Vasant Narasimhan while answering a question from an analyst during “Novartis First Quarter Conference Call” stated revised timelines of 2019 for the launch of Advair generic copy.
“we would expect to have to do a small bridging study, a bio-equivalence bridging study, but we don’t view this to be a significant hurdle for what we can see right now. So, our plan would be to get that study started and, as I said, stated to be ready for launch within 2019”
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about disease indications, visit https://pharmascroll.com/news/